Non-Hodgkin's lymphoma (NHL) is a group of malignancies of the immune system with variable clinical behaviors and diverse molecular features. Despite the progress made in classification of NHLs based on classical methods, molecular classifications are a work in progress. Toward this goal, we used an arraybased technique called differential methylation hybridization (DMH) to study small B-cell lymphoma (SBCL) subtypes. A total of 43 genomic DMH experiments were performed. From these results, several statistical methods were used to generate a set of differentially methylated genes for further validation. Methylation of LHX2, POU3F3, HOXC10, NRP2, PRKCE, RAMP, MLLT2, NKX6.1, LRP1B and ARF4 was validated in cell lines and patient samples and demonstrated subtype-related preferential methylation patterns. For LHX2 and LRP1B, bisulfite sequencing, real-time reverse transcriptase-polymerase chain reaction and induction of gene expression following treatment with the demethylating agent, 5 0 -aza-2 0 -deoxycytidine, were confirmed. This new epigenetic information is helping to define molecular portraits of distinct subtypes of SBCL that are not recognized by current classification systems and provides valuable potential insights into the biology of these tumors.
Introduction
Every year, approximately 54 000 new cases of non-Hodgkin's lymphoma (NHL) are diagnosed in the US. B-cell chronic lymphocytic leukemia (B-CLL)/small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL) and follicular lymphoma (FL), referred to as small B-cell lymphoma (SBCL), compromise nearly one-third of all NHL cases. 1 Current classification systems are based on clinical staging, chromosomal abnormalities 2 and cell surface antigens, and offer important diagnostic information. However, there is still considerable overlap in biology, clinical behavior and genetic and epigenetic alterations among the SBCL subtypes. DNA methylation within the CpG island (CGI) in promoter (and other) regions plays an important role in cancers by potentially silencing a broad spectrum of genes. 3 Aberrant patterns of CGI methylation are not random, but tumor type-specific, and can influence the gene expression profile. 4 DNA hypermethylation of some genes such as p57(KIP2), p15(INK4B), 5, 6 DAPK, 7 SHP-1 8 and p73 9 are frequent occurrences in lymphoid malignancies.
The SBCL subtypes are B-cell malignancies that correspond to different stages of normal B-cell differentiation and differ in clinical behavior. Whereas B-CLL/SLL and FL are generally indolent, MCL is more rapidly progressive. B-CLL/SLL is not one disease but is comprised of at least two biological subtypes representing pre-germinal center and post-germinal center B cells. 10 MCL is a pre-germinal center-derived malignancy, and FLs are of germinal center derivation. Expression microarray studies have provided information to assess clinical aggressiveness and guide the choice of treatment in FL. 11 Alizadeh et al. 12 used a lymphochip to monitor gene expression signatures of diffuse large B-cell lymphoma subgroups derived from distinct stages of B-cell differentiation. In addition, tumor classification can also be achieved by microarray-based DNA methylation profiling. 13 Few published reports have focused on the identification of genes whose methylation profiles differ between currently recognized SBCLs. Rush et al., 14 using Restriction Landmark Genomic Scanning, studied global CGI methylation in 10 CLL patient samples. Secreted Frizzled Related Protein gene family, a negative regulator of the Wnt signaling pathway, was found to be frequently methylated in CLL patients. 15 In this study, we used a high throughput approach to classify SBCL subtypes (43 patient samples). Hierarchical clustering 16 of the DNA methylation data was used to group each subtype on the basis of similarities in their DNA methylation patterns. Our data revealed that there is diversity in DNA methylation among the different SBCL subtypes, and some genes were preferentially methylated in a subtype-related manner. The main purpose of this study was to move closer to determination of epigenetic signatures of SBCLs based on DNA gene promoter methylation profiling.
Materials and methods

Patient samples
Tissue and blood samples were obtained from patients following diagnostic evaluation, in compliance with the Local Institutional Review Board. DNA was isolated from a total of 43 patient samples and control DNA was isolated from peripheral blood collected from seven healthy male and seven healthy female volunteers with mean age o30 years. These samples were pooled separately as NL1 (female) and NL2 (male). The QIAamp DNA Blood Minikit (Qiagen, Valencia, CA, USA) was used to purify genomic DNA. Samples from 15 patients with FL, 12 with MCL and 16 with B-CLL/SLL were used in this study. All cases of B-CLL/SLL had peripheral blood and bone marrow involvement and therefore were technically categorized as chronic lymphocytic leukemia, but are referred to as B-CLL/SLL in this paper. All specimens contained 480% neoplastic cells as determined by flow cytometry (data not shown). Complete flow cytometry reports were available for 12 of 16 B-CLL/SLL patients used in this study; six patient samples were CD38 þ and 6 CD38À (data not shown). Cells from three patients with benign follicular hyperplasia (HP) were also obtained. Total RNA was extracted from four samples of normal peripheral blood lymphocytes, two normal lymph nodes (LNs), eight FL, 10 CLL and eight MCL patient samples using the RNeasy kit (Qiagen, Valencia, CA, USA).
Cell culture and demethylating agent treatment
Six NHL cell lines (RL, Daudi, DB, Raji, Granta 519 and Mec-1) were used to study methylation patterns across different subtypes of lymphoma. NHL cell lines RL, Granta519 and Mec-1 were treated with the demethylating agent 5 0 -aza-2 0 -deoxycytidine (5-Aza) (see Supplementary Materials and methods for details of cell culture and drug treatment protocols). DNA and RNA were isolated from these cells as described above.
CGI microarray, amplicon preparation and hybridization
Polymerase chain reaction (PCR) products (on average B500 bp) comprised a microarray panel of 8544 sequenced CGI clones and were prepared as described previously (Supplementary Materials and methods). 17, 18 DNA samples were prepared for hybridization as reported for the differential methylation hybridization (DMH) protocol. 17, 18 Fluorescence amplicons representing pools of methylated NHL DNA (Cy5) relative to normal DNA (Cy3) were combined in a gendermatched manner and co-hybridized to the CGI microarray as described. 17, 18 In female subjects, one copy of the X chromosome is largely inactivated by DNA methylation. Therefore, women are expected to exhibit methylation of one allele of certain genes, such as the androgen receptor gene, whereas this occurs only in malignancy in males. 19 
Microarray data analysis
Each spot on the slide appears as a colored dot comprised of red (Cy5) and green (Cy3). The intensity levels of red and green in each spot signify the amount of methylation found in cancer (red) and normal (green) cells. Both were background-corrected and global normalization was applied with the assumption that the methylation level of both cancer and normal cells is similar in most loci (red/green E1). After array normalization, an across-array analysis was performed for each spot. These filtered loci were then subjected to further statistical testing to determine which loci were differentially methylated across subtypes of NHL. The Kruskal-Wallis test, because of its ability to compare more than two data distributions and its nonparametric nature, was performed on the group of samples at each locus. The P-value threshold was calculated using the Benjamini and Hochberg method. 20 The loci corresponding to the P-values p (1) pp (2) p?pp (J) were classified as differentially methylated. Hierarchical clustering algorithms were used to separate SBCLs based on similarities in the DNA methylation patterns. 16 Nucleotide sequencing results came from the Der laboratory (Toronto, Canada)
http://derlab.med.utoronto.ca/CpGIslandsMain.php.
Sequence identification information was obtained by the BLAST method.
Methylation confirmation by methylation-specific PCR
The DNA methylation status of selected candidate genes from specific regions of the microarray clusters was confirmed using methylation-specific PCR (MSP) (Supplementary Materials and methods). Each set of primers was first optimized using cell line DNA and then confirmed using patient DNA. The following 10 selected genes were examined: MLLT2, LHX2, LRP1B, HOXC10, NKX6.1, ARF4, NRP2, RAMP and POU3F3. The primer sequences used to confirm selected genes are listed in Supplementary Table 1 and the MSP protocol was as described. 19 Primers were designed using MethPrimer (www.ur ogene.org/methprimer/index.html). Products (5-9 ml) were directly loaded on a 2.5-3% agarose gel stained with SYBR Green (Cambrex Bio Science Rockland, ME, USA), visualized under UV light and captured using Kodak gel documentation system.
Bisulfite genomic sequencing analysis
Genomic DNA was treated with sodium bisulfite (see Supplementary Materials and methods). Primer sequences and PCR conditions are listed in Supplementary Table 2. Amplified PCR products for the LHX2 and LRP1B genes were subcloned using the TOPO-TA cloning system (Invitrogen, Carlsbad, CA, USA). Plasmid DNA of 6-8 insert positive clones was isolated using the Montage Plasmid Miniprep 96 kit (Millipore Corporation, Billerica, MA, USA) and sequenced using ABI 3730 sequencing systems (Applied Biosystems, Foster City, CA, USA).
Real-time RT-PCR
Two micrograms of RNA was reverse transcribed in the presence of SuperScript II reverse transcriptase (Invitrogen, Carlabad, CA, USA). The generated cDNA was used for SYBR green-based reverse transriptase (RT)-PCR amplifications with appropriate reagents in the ABsolute QPCR SYBR mix (AB gene, Rochester, NY, USA) as recommended by the manufacturer. The real-time RT-PCR was carried out in an iCycler iQ (BioRad, Hercules, CA, USA). Quantitative expression of four genes (LRP1B, LHX2, ARF4 and POU3F3) was measured in three SBCL cell lines (RL, Mec-1 and Granta519) before and after treatment with the demethylating agent 5-Aza. Relative expression of LHX2 and LRP1B was further studied in subsets of patient samples. It is important to note that, owing to sample limitations, these samples are not all from the same patients that we studied in microarray and MSP analysis. Each experiment was repeated three times and the median was calculated. For quantification, the ratio of target gene to reference gene (HRPT1) for each gene was calculated as 2
ÀDDCt where C t is the cycle threshold. iCycler conditions were as follows: 45 cycles with 15 s at 951C, 30 s at 601C (for ARF4, LRP1B), 641C (for POU3F3) and 681C for LHX2 and 30 s at 721C. Melt curve analysis was always performed after each run. The primer sequences are summarized in Supplementary Table 3 .
Statistical analysis
For comparisons of gene promoter methylation between classes of NHLs, the w 2 statistic was employed (Table 1 ). All the analyses were implemented in SAS (Statistical Analysis Software).
Results
Segregation of SBCL subtypes by hierarchical clustering
Genomic DNA methylation microarrays were used to characterize these SBCLs. A total of 15 de novo patient samples from those with FL, 16 B-CLL/SLL, 12 MCL and three samples of HP were all probed for the presence of methylated DNA, mainly in the promoter and first exon regions of genes and initially analyzed by hierarchical clustering as shown in Figure 1 . The upper dendrogram illustrates the relationships of patient samples to each other on the basis of DNA methylation patterns; those most alike cluster under a single branch of the dendrogram. In all, 256 CGI loci were selected based on statistical testing as described above. For each CGI locus of interest, the related gene was identified by searching the associated database of CGI sequences found at the Der laboratory web site. Moving from left to right represents a 'drilling down' into the microarray data to ultimately discover named genes that are differentially methylated candidates. For example, the branch indicated by the purple horizontal bar includes all the MCL samples, but no other samples. This separation appears to involve mainly clusters of gene loci from within regions A and D of the overall hierarchical cluster, as well as the paucity of methylated loci from within regions B and C where considerable methylation is indicated for FL and a subset of B-CLL/SLL samples. Thus, the observed patterns in MCL patients were distinct from FL and a subset of B-CLL/SLL patients, but associated with another subset of B-CLL/SLL indicated by the green horizontal bar. Further analysis of the profiles separated the B-CLL/SLL patients into two distinct groups. Seven of 16 (44%) B-CLL/SLL samples (indicated by the green horizontal bar) clustered adjacent to MCL, an aggressive pre-germinal center subtype of NHL. 1 Flow cytometry revealed that 2/7 (28%) of these were CD38 þ , 3/7 (43%) were CD38À; flow cytometry results were not available for the remaining two samples. Conversely, 9/16 (56%) B-CLL/SLL samples clustered with FL (indicated by the red horizontal bar). Of these, 4/9 (43%) were CD38 þ , 3/9 (33%) were CD38À; flow cytometry results were not available for the remaining two samples. Although there is no clear association of methylation with CD38 expression, this observation still suggests that DNA methylation patterns in B-CLL/SLL may not be homogeneous and perhaps methylation patterns relate to unrecognized subsets of B-CLL/SLL. A larger study of gene methylation specifically in B-CLL/SLL is currently under way and should address this issue. Those B-CLL/SLL samples that clustered near MCL (green horizontal bar) were characterized in the overall cluster as having few loci illustrated as methylated in regions A, B and C, but a small block within region D was conspicuously indicated as hypermethylated, similar to block D in MCL cases.
Cells from FL are similar in their biological characteristics to cells found in germinal centers of LNs. From a quantitative standpoint, there appear to be more CGI loci hypermethylated in FL patients than in MCL and a subset of B-CLL/SLL samples ( Figure 1) . Therefore, to further examine relationships between classes, these data were reclustered in a pairwise manner (Supplementary Figure 1) . Sequence characterization and chromosomal location of differentially methylated CGI loci are shown in Supplementary Table 4 . Most of these loci are located in the promoter or the first exon regions of known genes with a known function, but in some cases these loci are found in introns.
Confirmation of microarray findings
Microarrays are excellent discovery tools, but additional confirmation of selected results is prudent. In order to independently confirm the DNA methylation status of 10 known genes (NKX6.1, LRP1B, MLLT2, LHX2, ARF4, HOXC10, RAMP, NRP2, POU3F3 and PRKCE) selected to represent each region of the hierarchical clusters, MSP primers were produced and the conditions optimized using a series of NHL cell lines ( Figure 2 ) and then confirmed in SBCL patients (Figure 3 ). Eight of these 10 genes were methylated in both cell lines and in de novo NHL tumors. The MLLT2 and RAMP genes were examined, but were not methylated in any patient samples by MSP despite the methylation shown in the RL cell line (Figure 2) . Thus, these genes were not included in any further analyses. Hypermethylation of only one gene, LIM homeobox protein 2 (LHX2), was present in all NHL cell lines and a high proportion of patient samples, whereas the remaining genes were differentially methylated in the various cell lines, an observation that would be expected given the relationships of the cell lines to various stages of differentiation. Interestingly, the remaining genes were predominantly methylated in the germinal center-derived cell lines, but less so in Granta 519 and Mec-1 cell lines derived from MCL and B-CLL/SLL, respectively.
Analysis of CGI methylation patterns in de novo SBCL samples
Consistency was found between promoter methylation of the selected genes in NHL cell lines and primary NHLs, with the Novel epigenetic markers in SBCL FB Rahmatpanah et al exception of MLLT2 and RAMP. The eight genes confirmed as above were examined in 42 NHL patient samples using MSP (Figure 3 ). For each of the genes confirmed in patient samples, there was a higher incidence of DNA methylation in germinal center-related FL than in pre-germinal center-related NHLs (MCL and B-CLL/SLL) ( Figure 3 ). For instance, methylation of POU3F3 was observed in 3/16 (19%) B-CLL/SLL cases, 5/12 (41.6%) MCL cases and 13/15 (87%) FL cases (Pp0.01). Owing to the nature of the disease, patient samples were not purely tumor DNA (480% neoplastic cells) ; therefore, the unmethylated allele that amplified in each patient sample represents either normal tissue found within the tumor or the heterogeneity of methylation within the tumor sample itself. It is important to point out that MSP is more sensitive in identifying one locus at a time. However, the technique (DMH) we used to generate a hierarchical clustering algorithm is for large-scale interrogation of highly methylated CGI loci. Therefore, the frequencies of methylation shown in MSP do not always strictly correlate with DMH results.
The percentage of patient samples methylated in each gene promoter, and the statistical significance of these observations using the w 2 test are presented in Table 1 . For instance, in the comparison of B-CLL/SLL with MCL, of the eight gene promoters examined, only ARF4 (Pp0.001) and HOXC10 (Pp0.05) revealed differences at Po0.05. For the comparison of FL to B-CLL/SLL, five gene promoters were significantly different at Pp0.05: LRP1B, ARF4, NKX6-1, POU3F3 and NRP2; but in comparison of FL to MCL, only three gene promoters, LRP1B, POU3F3, and NRP2, were statistically different. In the case of POU3F3, although all three classes revealed DNA methylation, they were all highly different in proportion. Therefore, we were able to confirm that promoter DNA methylation (with the exception of LHX2, third intron), as discovered in the microarray experiments, was present in eight of the 10 genes tested in de novo SBCL samples, whereas all 10 were methylated in NHL cell lines. Figure 2 MSP validation of a subset of candidate genes from microarray studies using NHL cell lines. One microgram of genomic DNA was bisulfite treated, then PCR was performed for 35 cycles with primers specific for methylated (M) or unmethylated (U) templates and the products were analyzed on 3% agarose gel. Normal female (NL1) and male (NL2) peripheral blood lymphocyte DNA was used as negative controls and in vitro-methylated DNA using SssI methyltransferase was the positive control. 
Bisulfite genomic sequencing of LRP1B and LHX2
To further evaluate the quality of the array data, we used bisulfite sequencing to assess the methylation status of each CpG dinucleotide within the two CGI loci that were found to be differentially methylated (Supplementary Figure 2a) . Consistent with microarray and MSP analysis, two out of three MCL patient samples showed high levels of DNA methylation in CGI of LRP1B, whereas all three B-CLL/SLL patient samples had no or very low levels of methylation (Supplementary Figure 2b) . Conversely, LRP1B tended to be extensively methylated in three FL patient samples. Bisulfite sequencing of in vitro-methylated DNA (SssI-treated DNA) showed dense methylation in CG sites, whereas normal blood showed no methylation in that region. Moreover, bisulfite sequencing of LRP1B in NHL cell lines was in complete agreement with MSP results (Supplementary Figure  2b) . We also studied DNA methylation patterns of LHX2 that is known to be a biomarker in early B-cell differentiation. 21 The NHL cell lines displayed a near-complete methylation of the LHX2 amplified fragment. In primary tumors, LHX2 showed a heterogeneous pattern of DNA methylation in CpG dinucleotide sites (Supplementary Figure 2b) . It is important to mention that the lower frequency of methylation in primary tumor compared to the corresponding cell lines could be the result of contamination of the primary tumor (80% tumor cells) with the normal lymphoid tissues and unavailability of corresponding normal sample, causing underestimation.
To assess the extent to which the MSP results were confirmed by bisulfite sequencing, the k statistic (a type of intra-class correlation) was computed for LHX2 and LRP1B. Based on this statistical analysis, the agreement between MSP and bisulfite sequencing is 54% greater than what would be expected by chance. Overall, the proportion of agreement is 79% (19/24) 22 (see Supplementary Materials and methods for details).
Epigenetic reactivation of methylated genes
To determine whether the differential methylation was associated with gene silencing and to explore the effect of demethylation on restoring the expression of LRP1B, LHX2, POU3F3 and ARF4 in NHL cell lines, we conducted quantitative real-time RT-PCR, with each sample run in triplicate, and the median was calculated. Results illustrated in Supplementary  Figure 3a show that all of these genes were either expressed at low levels or undetectable in the cell lines before treatment. Induction of these genes occurred after treatment with 1 mm 5-Aza, with the exception of LHX2 in the Granta 519 cell line.
LRP1B and LHX2 mRNA expression in primary SBCL samples
We then assessed levels of LRP1B and LHX2 mRNA in primary SBCL tumor cells and non-malignant lymphoid cells. Results shown in Supplementary Figure 3b indicate that LRP1B is detectable at low levels in FL, B-CLL/SLL and MCL compared to the normal peripheral blood lymphocytes by at least 100-fold. Within the SBCL group, LRP1B mRNA expression was highest in MCL patients compared to FL and B-CLL/SLL, in spite of showing a high frequency of methylation by bisulfite sequencing. It should be noted that the actual patient samples used for expression analysis and bisulfite sequencing were not all the same owing to sample limitations. We also tested LHX2 expression (Supplementary Figure 3b) , and found low levels of mRNA in all three types of SBCL, as well as in normal LN samples, compared to normal peripheral blood lymphocytes. This observation is consistent with that of Xu et al. 21 in that precursor B cells have high levels of LHX2 expression, whereas more mature B cells have lower levels of expression. The higher levels in normal peripheral blood lymphocytes are likely a reflection of the presence of mainly T cells, where there does not appear to be a differentiation-related expression pattern.
Discussion
It is now becoming clear that despite the enormous contribution of the Human Genome Project to developing a sequence of human DNA, this is just the beginning in terms of understanding the human cancer genome. An entire area of non-sequencerelated alterations known as epigenetics is now accepted as having profound effects on human cells. Thus, there is a need to further dissect the cancer epigenome. Some of these epigenetic alterations include the methylation and/or acetylation status of histones, hypomethylation of genomic DNA and hypermethylation of gene promoter DNA, as well as others yet to be described. 23, 24 The epigenome becomes even more important because there has been a great deal of recent development of pharmaceutical interventions that can potentially reverse epigenetic alterations. 3, 25, 26 It is toward the goal of characterizing the human lymphoma epigenome that this study of three classes of NHL was undertaken.
The SBCLs exhibit a spectrum of clinical behaviors and the cell of origin of each subtype is thought to be related to a putative stage of normal B-cell differentiation. The mutational status of the variable region of immunoglobulin heavy chain (V H ) genes is a useful marker for identifying different developmental stages of NHLs and relates to processes that occur in the germinal center reaction. MCL is considered to arise in cells at the pre-germinal center stage where V H genes have not yet become mutated. 27 In FL, somatic hypermutation of V H genes characteristic of the germinal center reaction suggests that this class of NHL derives from a germinal center stage of differentiation. Approximately half of B-CLL/SLL cases are CD38 þ with unmutated V H genes (poor prognosis) and the remaining half are CD38À with mutated V H genes (better prognosis). Thus, B-CLL/SLL may represent two separate stages of differentiation: pre-germinal center and post-germinal center. The SBCL subtypes studied represent a spectrum of pre-germinal center, germinal center and post-germinal center stages of B-cell differentiation and provide a good model to study epigenetic alterations as they might relate to the various compartments of secondary lymphoid tissue cell differentiation.
High-throughput technologies have clearly advanced our understanding of the gene expression repertoire of human tumors. However, such studies do not address the underlying reason(s) for changes in gene expression. The CGI microarray was utilized to investigate part of the NHL epigenome of SBCL subtypes based on interrogation of promoter DNA methylation, a process that plays a role in human cancers by frequently silencing not only tumor suppressor genes, but also genes that are critical to the normal functions of cells (reviewed by Egger et al. 3 and Laird 3 ). A study conducted in our laboratory using a methylation-specific oligonucleotide microarray on SBCLs (actual patient samples used in this study were completely different from those that we included in our current study) identified different sets of genes that are of biological interest and represent candidate diagnostic and prognostic markers. 28 Our statistical analysis of data from the CGI microarray identified approximately 256 named, variably methylated genes within SBCL subtypes and recognized genes that are important to many intracellular processes. Additional CGI loci were also differentially methylated, but at this time, some are hypothetical genes and some have not yet been investigated for identity. The LHX2 gene belongs to a superfamily of homeobox-containing genes conserved during evolution and functions as a transcriptional regulatory protein in the control of lymphoid and neural cell differentiation, 21 found to be methylated by our array data, MSP and bisulfite sequencing across all the NHL cell lines and subsets of SBCL patient samples. In B-cell differentiation, LHX2 was found to be expressed in early stages of B-cell differentiation but not in plasmacytoma cell lines. 21 Low levels of LHX2 expression were detected in FL, CLL and MCL patient samples, which are also more mature B cells. The POU family proteins (POU3F3) also act as transcriptional factors and regulate tissuespecific gene expression at different stages of development in the nervous system, 29 and POU3F3 is preferentially methylated in FL patients, as was non-kinase neuropilin 2 (NRP2). This gene encodes a member of the neuropilin family of receptors that binds to SEMA3C (sema domain, Ig domain, short basic domain, secreted, semaphoring 3C) protein and also interacts with vascular endothelial growth factor, 30 an important mediator of angiogenesis. Additionally, ADP ribosylation factor 4 (ARF4), which plays a role in vesicular trafficking and as an activator of phospholipase D, was methylated in 7/12 (58.3%) MCL and 13/15 (87%) FL cases (Pp0.001). Phospholipase D is an enzyme involved in the CD38 signaling pathway and regulates lymphocyte activation and differentiation. 31 The LRP1B gene is frequently deleted in various tumor types, but this study shows a higher frequency of gene promoter methylation in germinal center SBCLs compared to the other subtypes (Pp0.001). CGI promoter hypermethylation of this gene has also been detected in esophageal squamous cell carcinomas. 32 This study demonstrates the value of the high-throughput CGI microarray 18 in cancer research. In a recent study 33 comparing this 9K library to another containing 12 192 (12K) clones, only 753 were found to be common between the two libraries, thus suggesting that the present study examined B50% of potential MseI-restricted CGI sequences in the human genome. Nevertheless, this does not diminish the value of finding many new, epigenetically altered genes that segregate with subclasses of NHL. Additional, more targeted, studies using the 12K CGI library are currently in process and should further advance our attempts to begin addressing the human lymphoma epigenome. The study also illustrates a very interesting biological finding: preferential methylation of multiple gene promoters in germinal center tumors such as FL compared to pre-germinal center tumors (MCL and some B-CLL/SLL) and post-germinal center tumors (subset of B-CLL/SLL). The reasons for this are not entirely clear, but may be related to the ongoing somatic hypermutations and the process of DNA strand breaks and repair (both effective and ineffective) that accompanies germinal center biology, and may be possibly carried over into germinal center NHLs. The findings of this study provide a basis for further investigations of gene promoter DNA methylation in NHLs and insights into the functional epigenomic signatures of human lymphomas as a prelude to characterizing and understanding the cancer epigenome.
